Bristol Receivables Trend from 2010 to 2020

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers Trade and Non Trade Receivables yearly trend continues to be fairly stable with very little volatility. Trade and Non Trade Receivables will likely drop to about 6.7 B in 2020. During the period from 2010 to 2020, Bristol Myers Trade and Non Trade Receivables regression line of anual values had slope of 448,185,167 and arithmetic mean of  4,816,315,789. Bristol Myers Consolidated Income is fairly stable at the moment as compared to the past year. Bristol Myers reported Consolidated Income of 3.46 Billion in 2019. Net Income to Non Controlling Interests is likely to grow to about 21.6 M in 2020, whereas Direct Expenses is likely to drop slightly above 6.5 B in 2020.

Search Historical Trends

 
Refresh
Check Bristol Myers financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 6.5 B, Consolidated Income of 3.5 B or Cost of Revenue of 7.3 B, as well as many exotic indicators such as Interest Coverage of 9.25, Long Term Debt to Equity of 0.91 or Calculated Tax Rate of 26.35. This can be a perfect complement to check Bristol Myers Valuation or Volatility. It can also complement various Bristol Myers Technical models. Continue to the analysis of Bristol Myers Correlation with competitors.

Bristol Receivables Marginal Breakdown

Showing smoothed Receivables of Bristol Myers Squibb with missing and latest data points interpolated.
Receivables10 Years Trend
Increasing
Slightly volatile
 Receivables 
      Timeline 

Bristol Receivables Regression Statistics

Arithmetic Mean 4,034,700,957
Geometric Mean 3,514,581,406
Coefficient Of Variation 56.97
Mean Deviation 1,868,528,491
Median 3,159,000,000
Standard Deviation 2,298,640,457
Range 6,384,710,526
R-Value 0.92
R-Squared 0.84
Significance 0.00007064
Slope 635,595,933

Bristol Receivables Over Time

20102.2 B
20112.4 B
20121.9 B
2013B
20142.3 B
20153.2 B
2016B
20175.1 B
20185.4 B
20197.7 B
20208.3 B

Other Fundumenentals of Bristol Myers Squibb

About Bristol Myers Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's Receivables, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and GW Pharmaceuticals Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol Myers Correlation with competitors. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page